Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930 | 0.87 | ALDH1A1 (0.59) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL18100124 | 0.83 | SMN1; SMN2 (0.62) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL1901172 | 0.80 | ALDH1A1 (0.76) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL18100115 | 0.80 | TGM2 (0.58) | — | |
| SCHEMBL9946007 | 0.78 | HDAC3 (0.47) | — | |
| SCHEMBL9945929 | 0.77 | SMN1; SMN2 (0.59) | ALDH1A1HSD17B10RAB9APOLBNAPRT | |
| SCHEMBL2556313 | 0.77 | MAPT (0.62) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL20221426 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CYP1A2RAB9APOLBSMN1; SMN2 | |
| SCHEMBL1015209 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HSD17B10CYP1A2RAB9APOLB | |
| SCHEMBL7023178 | 0.74 | ALDH1A1 (0.61) | ALDH1A1HSD17B10CYP1A2RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9480166-B2 | Method of manufacturing non-firing type electrode | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| US-20140306165-A1 | METHOD OF MANUFACTURING NON-FIRING TYPE ELECTRODE | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-10-16 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ALDH1A1 4010/4885HSD17B10 3109/4885CYP1A2 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.